Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil- activating chemokine

dc.contributor.authorDahinden, Clemensdeu
dc.contributor.authorGeiser, Thomasdeu
dc.contributor.authorBrunner, Thomas
dc.contributor.authorTscharner, Vinzenz vondeu
dc.contributor.authorCaput, Danieldeu
dc.contributor.authorFerrara, Pascualdeu
dc.contributor.authorMinty, Adriandeu
dc.contributor.authorBaggiolini, Marcodeu
dc.date.accessioned2011-11-09T09:27:44Zdeu
dc.date.available2011-11-09T09:27:44Zdeu
dc.date.issued1994
dc.description.abstractCC chemokines constitute a novel class of cytokines that attract and activate monocytes and lymphocytes, as well as basophil and eosinophil leukocytes, with distinct target cell profiles, and are believed to be involved in the regulation of different types of inflammation. The action of the recently identified monocyte chemotactic protein 3 (MCP-3) on human basophil and eosinophil function was studied and compared with that of other CC chemokines. In basophils, MCP-3, MCP-1, RANTES, and macrophage inflammatory protein (MIP)-1 alpha all induced cytosolic-free calcium concentration ([Ca2+]i) changes and, with different efficacies, chemotaxis (RANTES = MCP-3 > MCP-1 > MIP-1 alpha), histamine release (MCP-1 = MCP-3 > RANTES > MIP-1 alpha), and leukotriene C4 formation, after IL-3 pretreatment (MCP-1 = MCP-3 > RANTES > MIP-1 alpha). Thus, MCP-3 was as effective as MCP-1 as an inducer of mediator release, and as effective as RANTES as a stimulus of basophil migration. In contrast to MCP-1, MCP-3 was also a stimulus for eosinophils, and induced [Ca2+]i changes and chemotaxis as effectively as RANTES, which is the most potent chemotactic cytokine for these cells. Desensitization of the transient changes in [Ca2+]i was used to assess receptor usage. In basophils, stimulation with MCP-3 prevented responsiveness to MCP-1 and RANTES, but not to MIP-1 alpha. No single CC chemokine (except for MCP-3 itself) affected the response to MCP-3, however, which was prevented only when the cells were prestimulated with both MCP-1 and RANTES. In eosinophils, by contrast, cross-desensitization between RANTES and MCP-3 was obtained. RANTES and to a lesser extent MCP-3 also desensitized eosinophils toward MIP-1 alpha. The desensitization data suggest the existence of three chemokine receptors: (a) a MCP-1 receptor expressed on basophils but not eosinophils that is activated by MCP-1 and MCP-3; (b) a RANTES receptor in basophils and eosinophils that is activated by RANTES and MCP-3; and (c) a MIP-1 alpha receptor that is activated by MIP-1 alpha, RANTES and, more weakly, by MCP-3. This study shows that MCP-3 combines the properties of RANTES, a powerful chemoattractant, and MCP-1, a highly effective stimulus of mediator release, and thus has a particularly broad range of activities toward both human basophil and eosinophil leukocytes.eng
dc.description.versionpublished
dc.identifier.citationFirst publ. in: Journal of Experimental Medicine ; 179 (1994), 2. - pp. 751-756deu
dc.identifier.doi10.1084/jem.179.2.751deu
dc.identifier.ppn352861088deu
dc.identifier.urihttp://kops.uni-konstanz.de/handle/123456789/16638
dc.language.isoengdeu
dc.legacy.dateIssued2011-11-09deu
dc.rightsterms-of-usedeu
dc.rights.urihttps://rightsstatements.org/page/InC/1.0/deu
dc.subject.ddc570deu
dc.titleMonocyte chemotactic protein 3 is a most effective basophil- and eosinophil- activating chemokineeng
dc.typeJOURNAL_ARTICLEdeu
dspace.entity.typePublication
kops.citation.bibtex
@article{Dahinden1994Monoc-16638,
  year={1994},
  doi={10.1084/jem.179.2.751},
  title={Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil- activating chemokine},
  number={2},
  volume={179},
  issn={0022-1007},
  journal={Journal of Experimental Medicine},
  pages={751--756},
  author={Dahinden, Clemens and Geiser, Thomas and Brunner, Thomas and Tscharner, Vinzenz von and Caput, Daniel and Ferrara, Pascual and Minty, Adrian and Baggiolini, Marco}
}
kops.citation.iso690DAHINDEN, Clemens, Thomas GEISER, Thomas BRUNNER, Vinzenz von TSCHARNER, Daniel CAPUT, Pascual FERRARA, Adrian MINTY, Marco BAGGIOLINI, 1994. Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil- activating chemokine. In: Journal of Experimental Medicine. 1994, 179(2), pp. 751-756. ISSN 0022-1007. Available under: doi: 10.1084/jem.179.2.751deu
kops.citation.iso690DAHINDEN, Clemens, Thomas GEISER, Thomas BRUNNER, Vinzenz von TSCHARNER, Daniel CAPUT, Pascual FERRARA, Adrian MINTY, Marco BAGGIOLINI, 1994. Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil- activating chemokine. In: Journal of Experimental Medicine. 1994, 179(2), pp. 751-756. ISSN 0022-1007. Available under: doi: 10.1084/jem.179.2.751eng
kops.citation.rdf
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/16638">
    <dc:contributor>Ferrara, Pascual</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dc:creator>Ferrara, Pascual</dc:creator>
    <dspace:hasBitstream rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/16638/1/1994_Dahinden_MCP3.pdf"/>
    <dc:contributor>Caput, Daniel</dc:contributor>
    <dcterms:rights rdf:resource="https://rightsstatements.org/page/InC/1.0/"/>
    <dc:creator>Baggiolini, Marco</dc:creator>
    <dcterms:hasPart rdf:resource="https://kops.uni-konstanz.de/bitstream/123456789/16638/1/1994_Dahinden_MCP3.pdf"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-11-09T09:27:44Z</dc:date>
    <dc:contributor>Baggiolini, Marco</dc:contributor>
    <dcterms:issued>1994</dcterms:issued>
    <dcterms:title>Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil- activating chemokine</dcterms:title>
    <dc:creator>Minty, Adrian</dc:creator>
    <dcterms:bibliographicCitation>First publ. in: Journal of Experimental Medicine ; 179 (1994), 2. - pp. 751-756</dcterms:bibliographicCitation>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-11-09T09:27:44Z</dcterms:available>
    <dc:creator>Dahinden, Clemens</dc:creator>
    <dc:contributor>Geiser, Thomas</dc:contributor>
    <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/16638"/>
    <dcterms:abstract xml:lang="eng">CC chemokines constitute a novel class of cytokines that attract and activate monocytes and lymphocytes, as well as basophil and eosinophil leukocytes, with distinct target cell profiles, and are believed to be involved in the regulation of different types of inflammation. The action of the recently identified monocyte chemotactic protein 3 (MCP-3) on human basophil and eosinophil function was studied and compared with that of other CC chemokines. In basophils, MCP-3, MCP-1, RANTES, and macrophage inflammatory protein (MIP)-1 alpha all induced cytosolic-free calcium concentration ([Ca2+]i) changes and, with different efficacies, chemotaxis (RANTES = MCP-3 &gt; MCP-1 &gt; MIP-1 alpha), histamine release (MCP-1 = MCP-3 &gt; RANTES &gt; MIP-1 alpha), and leukotriene C4 formation, after IL-3 pretreatment (MCP-1 = MCP-3 &gt; RANTES &gt; MIP-1 alpha). Thus, MCP-3 was as effective as MCP-1 as an inducer of mediator release, and as effective as RANTES as a stimulus of basophil migration. In contrast to MCP-1, MCP-3 was also a stimulus for eosinophils, and induced [Ca2+]i changes and chemotaxis as effectively as RANTES, which is the most potent chemotactic cytokine for these cells. Desensitization of the transient changes in [Ca2+]i was used to assess receptor usage. In basophils, stimulation with MCP-3 prevented responsiveness to MCP-1 and RANTES, but not to MIP-1 alpha. No single CC chemokine (except for MCP-3 itself) affected the response to MCP-3, however, which was prevented only when the cells were prestimulated with both MCP-1 and RANTES. In eosinophils, by contrast, cross-desensitization between RANTES and MCP-3 was obtained. RANTES and to a lesser extent MCP-3 also desensitized eosinophils toward MIP-1 alpha. The desensitization data suggest the existence of three chemokine receptors: (a) a MCP-1 receptor expressed on basophils but not eosinophils that is activated by MCP-1 and MCP-3; (b) a RANTES receptor in basophils and eosinophils that is activated by RANTES and MCP-3; and (c) a MIP-1 alpha receptor that is activated by MIP-1 alpha, RANTES and, more weakly, by MCP-3. This study shows that MCP-3 combines the properties of RANTES, a powerful chemoattractant, and MCP-1, a highly effective stimulus of mediator release, and thus has a particularly broad range of activities toward both human basophil and eosinophil leukocytes.</dcterms:abstract>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Geiser, Thomas</dc:creator>
    <dc:rights>terms-of-use</dc:rights>
    <dc:creator>Brunner, Thomas</dc:creator>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Brunner, Thomas</dc:contributor>
    <dc:language>eng</dc:language>
    <dc:creator>Caput, Daniel</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Dahinden, Clemens</dc:contributor>
    <dc:creator>Tscharner, Vinzenz von</dc:creator>
    <dc:contributor>Tscharner, Vinzenz von</dc:contributor>
    <dc:contributor>Minty, Adrian</dc:contributor>
  </rdf:Description>
</rdf:RDF>
kops.description.openAccessopenaccessgreen
kops.flag.knbibliographyfalse
kops.identifier.nbnurn:nbn:de:bsz:352-166382deu
kops.sourcefieldJournal of Experimental Medicine. 1994, <b>179</b>(2), pp. 751-756. ISSN 0022-1007. Available under: doi: 10.1084/jem.179.2.751deu
kops.sourcefield.plainJournal of Experimental Medicine. 1994, 179(2), pp. 751-756. ISSN 0022-1007. Available under: doi: 10.1084/jem.179.2.751deu
kops.sourcefield.plainJournal of Experimental Medicine. 1994, 179(2), pp. 751-756. ISSN 0022-1007. Available under: doi: 10.1084/jem.179.2.751eng
kops.submitter.emailregina.fleischmann@uni-konstanz.dedeu
relation.isAuthorOfPublicationf61b843f-0378-4683-b89b-70ad6aec10ea
relation.isAuthorOfPublication.latestForDiscoveryf61b843f-0378-4683-b89b-70ad6aec10ea
source.bibliographicInfo.fromPage751
source.bibliographicInfo.issue2
source.bibliographicInfo.toPage756
source.bibliographicInfo.volume179
source.identifier.issn0022-1007
source.periodicalTitleJournal of Experimental Medicine

Dateien

Originalbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
1994_Dahinden_MCP3.pdf
Größe:
504.05 KB
Format:
Adobe Portable Document Format
1994_Dahinden_MCP3.pdf
1994_Dahinden_MCP3.pdfGröße: 504.05 KBDownloads: 469

Lizenzbündel

Gerade angezeigt 1 - 1 von 1
Vorschaubild nicht verfügbar
Name:
license.txt
Größe:
1.92 KB
Format:
Plain Text
Beschreibung:
license.txt
license.txtGröße: 1.92 KBDownloads: 0